Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541329 · ClinicalTrials.gov registry record · Phase 4
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT04541329 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 7 participants.
The verdict
NCT04541329, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
Interventions
- BIOLOGICAL Tildrakizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2023-01-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04541329
The ClinicalTrials.gov registry entry for NCT04541329 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tildrakizumab is the first listed.
NCT04541329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04541329 about?
NCT04541329 is a clinical study titled "Predicting Inflammatory Skin Disease Response to IL-23 Blockade". This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
What is the current status of trial NCT04541329?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2020-09-16. Estimated completion is 2023-01-15.
What interventions are being tested in trial NCT04541329?
The interventions under investigation include: Tildrakizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04541329?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.